Business Wire

SEOUL, South Korea--(BUSINESS WIRE)-- Magnachip Semiconductor Corporation (“Magnachip” or the “Company”) (NYSE: MX) celebrated the opening ceremony of Magnachip Technology Company, Ltd. ("MTC") today at its headquarters located in Hefei, China. MTC is a subsidiary of Magnachip, established on December 20, 2023, to expand the Company’s display driver IC and power IC businesses in China.

The ceremony was attended by local government officials and Company... (continue reading...)

PARIS--(BUSINESS WIRE)-- Just over a month after the Digital World Premiere, TUC.tiny is ready to make its debut at VivaTech 2024, the most important technology fair in Europe. In Hall 1, Pavilion 41, TUC S.r.l. will present to the public for the first time its latest technological innovation: TUC.tiny®, the Modular Dashboard concept, and the TUC.technology offering, developed to revolutionize the world of mobility.

TUC.tiny® is the compact version of the... (continue reading...)

PARIS--(BUSINESS WIRE)-- Ubitus K.K. (hereinafter Ubitus), a leading cloud gaming technology provider, is thrilled to announce its participation in Viva Technology 2024, Europe’s biggest startup and tech event, taking place from May 22nd to May 25th at Paris Expo Porte de Versailles. Visitors can explore Ubitus' innovative solutions at Booth D38 in the TTA Pavilion, Hall 1, where you can express your creativity through Ubitus’ AI solutions.

Innovative... (continue reading...)

HANOI, Vietnam--(BUSINESS WIRE)-- FPT Software, a leading global IT company, has earned HITRUST Risk-based, 2-year (r2) Certification for its Web Services System, Database System and Deployment System. This marks the second consecutive time that FPT Software achieved this recognition, underscoring its ongoing commitment to the highest standards of data protection and risk management.

This press release features multimedia. View the full release here: ... (continue reading...)

• Data on specific subgroups pave the way for new perspectives
• Continued commitment to conduct the phase 2/3 GREEN and phase 2b LIBERATE studies has been confirmed.

PARIS--(BUSINESS WIRE)-- Regulatory News:

ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, including stroke, announces the presentation, on... (continue reading...)